RT Journal Article
SR Electronic
T1 Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.14.22270780
DO 10.1101/2022.02.14.22270780
A1 Ditte Demontis
A1 G. Bragi Walters
A1 Georgios Athanasiadis
A1 Raymond Walters
A1 Karen Therrien
A1 Leila Farajzadeh
A1 Georgios Voloudakis
A1 Jaroslav Bendl
A1 Biao Zeng
A1 Wen Zhang
A1 Jakob Grove
A1 Thomas D. Als
A1 Jinjie Duan
A1 F. Kyle Satterstrom
A1 Jonas Bybjerg-Grauholm
A1 Marie Bækved-Hansen
A1 Olafur O. Gudmundsson
A1 Sigurdur H. Magnusson
A1 Gisli Baldursson
A1 Katrin Davidsdottir
A1 Gyda S. Haraldsdottir
A1 Trine Tollerup Nielsen
A1 Esben Agerbo
A1 Gabriel E. Hoffman
A1 Søren Dalsgaard
A1 Joanna Martin
A1 Marta Ribasés
A1 Dorret I. Boomsma
A1 Maria Soler Artigas
A1 Nina Roth Mota
A1 Daniel Howrigan
A1 Sarah E. Medland
A1 Tetyana Zayats
A1 Veera Manikandan
A1 ADHD Working Group of the Psychiatric Genomics Consortium
A1 iPSYCH-Broad Consortium
A1 Merete Nordentoft
A1 Ole Mors
A1 David M. Hougaard
A1 Preben Bo Mortensen
A1 Mark J. Daly
A1 Stephen V. Faraone
A1 Hreinn Stefansson
A1 Panos Roussos
A1 Barbara Franke
A1 Thomas Werge
A1 Benjamin M. Neale
A1 Kari Stefansson
A1 Anders D. Børglum
YR 2022
UL http://medrxiv.org/content/early/2022/02/16/2022.02.14.22270780.abstract
AB Attention deficit hyperactivity disorder (ADHD) is a prevalent childhood psychiatric disorder, with a major genetic component. Here we present a GWAS meta-analysis of ADHD comprising 38,691 individuals with ADHD and 186,843 controls. We identified 27 genome-wide significant loci, which is more than twice the number previously reported. Fine-mapping risk loci highlighted 76 potential risk genes enriched in genes expressed in brain, particularly the frontal cortex, and in early brain development. Overall, ADHD was associated with several brain specific neuronal sub-types and especially midbrain dopaminergic neurons. In a subsample of 17,896 exome-sequenced individuals, we identified increased load of rare protein-truncating variants in cases for a set of risk genes enriched with likely causal common variants, suggesting implication of SORCS3 in ADHD by both common and rare variants. We found ADHD to be highly polygenic, with around seven thousand variants explaining 90% of the SNP heritability. Bivariate gaussian mixture modeling estimated that more than 90% of ADHD influencing variants are shared with other psychiatric disorders (autism, schizophrenia and depression) and phenotypes (e.g. educational attainment) when both concordant and discordant variants are considered. Additionally, we demonstrated that common variant ADHD risk was associated with impaired complex cognition such as verbal reasoning and a range of executive functions including attention.Competing Interest StatementB.M.N. currently serve as a member of the scientific advisory board at Deep Genomics and Neumora (previously RBNC) and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen.Funding StatementD.D. was supported by the Novo Nordisk Foundation (NNF20OC0065561), the Lundbeck Foundation (R344 2020 1060) the European Unions Horizon 2020 research and innovation programme under grant agreement No. 965381(TIMESPAN). Research reported in this publication was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The work was also supported by the European College of Neuropsychopharmacology (ECNP) Network ADHD Across the Lifespan. B.F. was also supported by funding from the European Communitys Horizon 2020 Programme (H2020/2014 2020) under grant agreements No. 728018 (Eat2beNICE) and No. 847879 (PRIME). B.F. also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the Dutch National Science Agenda NeurolabNL project (grant 400 17 602). S.E.M. was funded by NHMRC grants APP1172917, APP1158125 and APP1103623. This work was supported by the Instituto de Salud Carlos III (PI19/01224, PI20/0004), by the Pla Estrategic de Recerca i Innovacio en Salut (PERIS), Generalitat de Catalunya (METAL Cat; SLT006/17/287) by the Agencia de Gestio dAjuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461), Ministry of Science, Innovation and Universities (IJC2018 035346 I to M.S.A); by the European Regional Development Fund (ERDF) and by la Marato de TV3 (092330/31) and the ECNP Network ADHD across the Lifespan (https://www.ecnp.eu/researchinnovation/ECNP networks/List ECNP Networks/). T.Z. is funded by NIH, Grant No. R37MH107649 07S1 and by Research Council of Norway, NRC, Grant No. 288083. This study was also supported by the National Institutes of Health (NIH), Bethesda, MD under award numbers T32MH087004 (to K.T.), K08MH122911 (to G.V.), R01MH125246 (to P.R.) and U01MH116442 (to P.R.). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The iPSYCH samples was approved by the Danish Data Protection Agency and the Scientific Ethics Committee in Denmark. The deCODE samples was approved by the National Bioethics Committee of IcelandI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors